Speclipse Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
13
Speclipse General Information
Description
Developer of a medical diagnostic platform intended to detect early symptoms of skin cancer, including melanoma. The company's platform uses laser-induced plasma spectroscopy and machine learning to support non-invasive skin cancer diagnosis, enabling doctors to detect early-stage skin cancer without compromising efficacy or accuracy and reducing the need for biopsies.
Contact Information
Website
www.speclipse.com(Operating Subsidiary)
Corporate Office
- 4th Floor, Gyeongchang Building
- 141, Unjung-ro, Bundang-gu
- Seongnam-si, Gyeonggi-do
- South Korea
Corporate Office
- 4th Floor, Gyeongchang Building
- 141, Unjung-ro, Bundang-gu
- Seongnam-si, Gyeonggi-do
- South Korea
Speclipse Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 19-May-2025 | Cancelled | Generating Revenue | |||
| 7. Later Stage VC | 28-Sep-2026 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 01-Jul-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 21-Aug-2021 | Completed | Generating Revenue | |||
| 4. Merger/Acquisition | 04-Nov-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 18-Nov-2016 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 18-Dec-2015 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Nov-2015 | Completed | Startup |
Speclipse Patents
Speclipse Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240219383-A1 | Device, system, and method of measuring concentration of analyte in bodily fluid sample | Inactive | 28-Dec-2022 | ||
| WO-2024143624-A1 | Devices, system, and method for measuring concentration of analyte in body fluid sample | Inactive | 28-Dec-2022 | ||
| EP-4364683-A1 | Diagnostic device with probe including camera | Pending | 07-Nov-2022 | ||
| US-12648813-B2 | Diagnostic device with probe including camera | Active | 07-Nov-2022 | ||
| US-20240148436-A1 | Diagnostic device with probe including camera | Active | 07-Nov-2022 | A61B5/0075 |
Speclipse Signals
Speclipse Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bluepoint | Venture Capital | Minority | ||
| InterVest | Venture Capital | Minority | ||
| JB Investment (Seoul) | Corporate Venture Capital | Minority | ||
| Kite Entrepreneur Foundation | Accelerator/Incubator | |||
| SBVA | Venture Capital | Minority |
Speclipse Acquisitions (1)
Speclipse’s most recent deal was a Merger/Acquisition with Korea Laser. The deal was made on 14-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Korea Laser | 14-Jun-2023 | Merger/Acquisition | Therapeutic Devices |
Speclipse FAQs
-
When was Speclipse founded?
Speclipse was founded in 2015.
-
Where is Speclipse headquartered?
Speclipse is headquartered in Seongnam-si, South Korea.
-
What is the size of Speclipse?
Speclipse has 12 total employees.
-
What industry is Speclipse in?
Speclipse’s primary industry is Diagnostic Equipment.
-
Is Speclipse a private or public company?
Speclipse is a Private company.
-
What is Speclipse’s current revenue?
The current revenue for Speclipse is .
-
How much funding has Speclipse raised over time?
Speclipse has raised $33.8M.
-
Who are Speclipse’s investors?
Bluepoint, InterVest, JB Investment (Seoul), Kite Entrepreneur Foundation, and SBVA have invested in Speclipse.
-
When was Speclipse acquired?
Speclipse was acquired on 19-May-2025.
-
Who acquired Speclipse?
Speclipse was acquired by Cell Return.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process